Artificial kidney

Trestle Biotherapeutics Wins Prestigious KidneyX Prize

Retrieved on: 
Monday, June 12, 2023
Health, Diabetes, Stem Cells, Health Technology, Other Health, General Health, Biotechnology, Tissue, Protalix BioTherapeutics, Cleveland Clinic, Partnership, Kidney failure, Chronic kidney disease, U.S. Department of Defense Strategy for Operating in Cyberspace, HHS, Artificial kidney, Office of Inspector General, U.S. Department of Health and Human Services, 3D, Survival, American Society of Nephrology, Dialysis, ASN, Patient, Kidney, Diagnosis, Cleveland, CKD, Society, Pharmaceutical industry, Trestle

Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program.

Key Points: 
  • Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program.
  • Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today.
  • Trestle was recognized for their innovative approach in developing bioengineered kidney tissues for patients living with kidney failure through the integration of cutting-edge techniques in stem cell biology and 3D biofabrication.
  • Of the work being done at Trestle, John Sedor, M.D., KidneyX Chair and nephrologist at the Cleveland Clinic, said, “We are thrilled to support ambitious, forward-thinking solutions for kidney failure patients like the ones being developed at Trestle Bio.

Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021

Retrieved on: 
Thursday, July 29, 2021
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Rockwell Medical, Hemodialysis, Dialysis, Nephrology, Artificial kidney

ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

Key Points: 
  • ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.
  • A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/ .
  • The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform.
  • In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

Top NIH Kidney Research Director Wins Prestigious Award from America's Premier Kidney Patient Group

Retrieved on: 
Monday, June 21, 2021
Medicine, Clinical medicine, Medical specialties, Membrane technology, Artificial kidney, Nephrology, Kidney transplantation, Dialysis, National Kidney Foundation, Kidney, Organ transplantation, Northwest Kidney Centers

The 2021 Summit highlighted innovation in kidney biologics, diagnostics, and devices, and examined opportunities and challenges for accelerating treatment innovations in artificial kidneys, transplantation, and dialysis.

Key Points: 
  • The 2021 Summit highlighted innovation in kidney biologics, diagnostics, and devices, and examined opportunities and challenges for accelerating treatment innovations in artificial kidneys, transplantation, and dialysis.
  • The Summit was dedicated to the memory of former AAKP Board Member Brian Hess, a long-time advocate for kidney patient care choice and a champion of The Kidney Project, a KidneyX prize-winning initiative aimed at developing an artificial kidney ( read now ).
  • Richard Knight, AAKP President, former dialysis patient, and 14-year kidney transplant recipient stated, "This award recognizes Dr. Rodgers' relentless dedication to the kidney patient community, public service, and America's historic role as a leader in advanced research, medical innovation, and kidney care treatments.
  • About the American Association of Kidney Patients (AAKP): Since 1969, AAKP has been the largest kidney patient organization driving policy discussions on kidney patient consumer care choice and treatment innovation.

Simple medical device improves care after kidney transplantation

Retrieved on: 
Tuesday, June 1, 2021
Anatomy, Medicine, Branches of biology, Kidney transplantation, Organ transplantation, Lawson Health Research Institute, Artificial kidney, Kidney

LONDON, June 1, 2021 /PRNewswire/ -- In a published study , a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.

Key Points: 
  • LONDON, June 1, 2021 /PRNewswire/ -- In a published study , a team from Lawson Health Research Institute (LHSC), in Ontario Canada, has found that a simple medical device can reduce swelling after kidney transplantation.
  • Patients using the device following kidney transplantation experienced shorter hospital stays and reduced surgical site infections by nearly 60 per cent.
  • The geko device has been adopted into the care pathway and is now being offered to patients at LHSC in recovery after receiving a new kidney.
  • "My surgeon explained in very simple terms that it was as if my new kidney wasn't awake yet," describes Garcia.

Innovative Renal Care Acquires Kidney Treatment Center of San Antonio

Retrieved on: 
Tuesday, April 6, 2021
General Health, Health, Other Health, Medicine, Membrane technology, Clinical medicine, Medical specialties, Detoxification, Dialysis, Kidney, Nephrology, Renal dialysis, Northwest Kidney Centers, Artificial kidney, Innovative Renal Care, Kidney Treatment Center San Antonio

Innovative Renal Care (IRC), a brand of American Renal Associates (ARA), announced today its acquisition of the assets of Kidney Treatment Center of San Antonio (KTC), an independently owned and operated patient-centered renal dialysis company offering highly personalized care to patients across three dialysis centers in San Antonio.

Key Points: 
  • Innovative Renal Care (IRC), a brand of American Renal Associates (ARA), announced today its acquisition of the assets of Kidney Treatment Center of San Antonio (KTC), an independently owned and operated patient-centered renal dialysis company offering highly personalized care to patients across three dialysis centers in San Antonio.
  • The three clinics, which are currently accepting new patients, will be renamed as IRC San Antonio - Medical Drive, IRC San Antonio - Castroville Road and IRC San Antonio - South New Braunfels.
  • Innovative Renal Care (IRC), an ARA brand, is a pioneering network of dialysis professionals devoted to helping people with kidney disease lead their best lives as they undergo treatment.
  • Our three Kidney Treatment Centers offer a variety of services to patients with end stage renal disease.

Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine

Retrieved on: 
Friday, March 12, 2021
Biotechnology, Pharmaceutical, Surgery, General Health, Health, FDA, Diabetes, Medical devices, Medicine, Clinical medicine, Membrane technology, Renal dialysis, Nephrology, Medical specialties, Hemodialysis, Artificial kidney, Dialysis, Baxter International, Clearance, Northwest Kidney Centers

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments.
  • The AK 98 dialysis machine is indicated to be used on patients with a body weight of 25kg or more.
  • This release includes forward-looking statements concerning the AK 98 dialysis machine and Theranova, including anticipated availability and potential benefits associated with their use.
  • Baxter, AK 98 and Theranova are registered trademarks of Baxter International Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005084/en/

Wearable Artificial Organs, Inc. Granted Patent for the Wearable Artificial Kidney (WAK) 3.0

Retrieved on: 
Wednesday, March 3, 2021
Health, Medical devices, Diabetes, Other Science, Clinical trials, Research, Science, Membrane technology, Nephrology, Artificial kidney, Medical specialties, Medicine, Artificial organ, Dialysis, Wearable, Clinical medicine

Victor Gura, MD, Chairman and Chief Scientific Officer of Wearable Artificial Organs Inc., announced today that the US Patent Office has granted approval of patent No.

Key Points: 
  • Victor Gura, MD, Chairman and Chief Scientific Officer of Wearable Artificial Organs Inc., announced today that the US Patent Office has granted approval of patent No.
  • Current stationary dialysis machines hinder mobility and limit activities in patients with End Stage Kidney Disease.
  • A miniaturized, battery operated wearable artificial kidney (WAK) can improve patient autonomy and has the potential to improve quality of life and reduce mortality.
  • ABOUT WEARABLE ARTIFICIAL ORGANS INC. (WAO)
    The company is a privately held Delaware corporation founded in 2017 to develop Dr. Guras latest invention.

End Stage Renal Disease Market Size Worth $193.8 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, January 27, 2021
Kidney diseases, Anatomy, Nephrology, Organ failure, Branches of biology, Artificial kidney, Membrane technology, Kidney failure, Chronic kidney disease, Kidney, Autosomal dominant polycystic kidney disease, Renal angina

SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.
  • The increasing number of patients suffering from end stage renal disease (also known as kidney failure) and the rising prevalence of hypertension and diabetes are fueling the market growth.
  • Technological advancements including the innovation of wearable artificial kidney (WAK) in the treatment of renal failure are expediting the overall market growth.
  • Grand View Research has segmented the global end stage renal disease market on the basis of treatment and region:
    End-Stage Renal Disease Treatment Outlook (Revenue, USD Million, 2016 - 2028)

End Stage Renal Disease Market Size Worth $193.8 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, January 27, 2021
Kidney diseases, Anatomy, Nephrology, Organ failure, Branches of biology, Artificial kidney, Membrane technology, Kidney failure, Chronic kidney disease, Kidney, Autosomal dominant polycystic kidney disease, Renal angina

SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.
  • The increasing number of patients suffering from end stage renal disease (also known as kidney failure) and the rising prevalence of hypertension and diabetes are fueling the market growth.
  • Technological advancements including the innovation of wearable artificial kidney (WAK) in the treatment of renal failure are expediting the overall market growth.
  • Grand View Research has segmented the global end stage renal disease market on the basis of treatment and region:
    End-Stage Renal Disease Treatment Outlook (Revenue, USD Million, 2016 - 2028)

Global Renal Dialysis Equipment Market Report 2020: Medical Devices Pipeline Assessment & Ongoing Clinical Trials Overview - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 13, 2021
Health, Clinical trials, Medical devices, Medicine, Clinical medicine, Membrane technology, Branches of biology, Endocrine system, Kidney, Dialysis, Renal dialysis, Assessment of kidney function, Northwest Kidney Centers, Artificial kidney

The "Renal Dialysis Equipment - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Renal Dialysis Equipment - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.
  • "Renal Dialysis Equipment - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Renal Dialysis Equipment pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Renal Dialysis Equipment is intended to provide an artificial replacement for lost kidney function due to renal failure.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date